<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><description>世事洞明皆学问，人情练达即文章</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 06 Apr 2021 10:12:28 +0800</pubDate><image><url>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</url><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>2020年中国Biotech融资TOP10</title><link>https://mp.weixin.qq.com/s/aTzPIys9ox7P-c5Xvg-Dww</link><description></description><content:encoded><![CDATA[2020年中国Biotech融资TOP10]]></content:encoded><pubDate>Tue, 06 Apr 2021 07:40:35 +0800</pubDate></item><item><title>林欣点评 | 攻克实体瘤新利器——STAR-T</title><link>https://mp.weixin.qq.com/s/vajTJkmn0GbTNR3aBViiqw</link><description></description><content:encoded><![CDATA[林欣点评 | 攻克实体瘤新利器——STAR-T]]></content:encoded><pubDate>Tue, 06 Apr 2021 07:40:35 +0800</pubDate></item><item><title>加快临床与上市，嘉和生物商业化进程全速推进  ​</title><link>https://mp.weixin.qq.com/s/_hQ_WWKyZYrxM3GLuWxNtQ</link><description></description><content:encoded><![CDATA[加快临床与上市，嘉和生物商业化进程全速推进  ​]]></content:encoded><pubDate>Tue, 06 Apr 2021 07:40:35 +0800</pubDate></item><item><title>德琪医药PAK4/NAMPT双靶点抑制剂ATG-019治疗晚期实体瘤和非霍奇金淋巴瘤临床试验申请在中国获批准</title><link>https://mp.weixin.qq.com/s/OPl7YRKAPNhgJvZMayXJzA</link><description></description><content:encoded><![CDATA[德琪医药PAK4/NAMPT双靶点抑制剂ATG-019治疗晚期实体瘤和非霍奇金淋巴瘤临床试验申请在中国获批准]]></content:encoded><pubDate>Tue, 06 Apr 2021 07:40:35 +0800</pubDate></item><item><title>Science：人类癌症与微生物组「图鉴」</title><link>https://mp.weixin.qq.com/s/waEch3HHDixIaUvjZsU8Uw</link><description></description><content:encoded><![CDATA[Science：人类癌症与微生物组「图鉴」]]></content:encoded><pubDate>Mon, 05 Apr 2021 08:07:33 +0800</pubDate></item><item><title>PD-1/PD-L1联合治疗全梳理：理想很丰满，现实很骨感</title><link>https://mp.weixin.qq.com/s/sK9SW2BlmGG9ucTj40CYsw</link><description></description><content:encoded><![CDATA[PD-1/PD-L1联合治疗全梳理：理想很丰满，现实很骨感]]></content:encoded><pubDate>Mon, 05 Apr 2021 08:07:33 +0800</pubDate></item><item><title>Nature：抗体偶联药开发概览及市场预测</title><link>https://mp.weixin.qq.com/s/ZdlsT1Fskdtt23bNAb3Gtg</link><description></description><content:encoded><![CDATA[Nature：抗体偶联药开发概览及市场预测]]></content:encoded><pubDate>Sat, 03 Apr 2021 08:55:32 +0800</pubDate></item><item><title>医药魔方Med招聘：医学编辑</title><link>https://mp.weixin.qq.com/s/SkZ0rzXxSzeyyGAswFmV7g</link><description></description><content:encoded><![CDATA[医药魔方Med招聘：医学编辑]]></content:encoded><pubDate>Sat, 03 Apr 2021 08:55:32 +0800</pubDate></item><item><title>上市还有希望吗？渤健阿尔茨海默症单抗aducanumab再遭FDA委员会抨击</title><link>https://mp.weixin.qq.com/s/4CWSgm6pMb_UHmUPDK5cUQ</link><description></description><content:encoded><![CDATA[上市还有希望吗？渤健阿尔茨海默症单抗aducanumab再遭FDA委员会抨击]]></content:encoded><pubDate>Sat, 03 Apr 2021 08:55:32 +0800</pubDate></item><item><title>邵峰 &amp; 邓天敬：纳百川，生万物</title><link>https://mp.weixin.qq.com/s/rYPuUkEt6peSCop1SGORCg</link><description></description><content:encoded><![CDATA[邵峰 & 邓天敬：纳百川，生万物]]></content:encoded><pubDate>Fri, 02 Apr 2021 07:37:05 +0800</pubDate></item><item><title>报名启动！BioChina中国生物医药创新高峰论坛</title><link>https://mp.weixin.qq.com/s/LXFG_h0ZDNz141V5rcHT4g</link><description></description><content:encoded><![CDATA[报名启动！BioChina中国生物医药创新高峰论坛]]></content:encoded><pubDate>Fri, 02 Apr 2021 07:37:05 +0800</pubDate></item><item><title>杨大俊点评 | 颠覆认知：p53“铁搭档”MDM2，竟是抗癌帮手</title><link>https://mp.weixin.qq.com/s/PNaISkCMpMolckiHIWPuOA</link><description></description><content:encoded><![CDATA[杨大俊点评 | 颠覆认知：p53“铁搭档”MDM2，竟是抗癌帮手]]></content:encoded><pubDate>Fri, 02 Apr 2021 07:37:05 +0800</pubDate></item><item><title>4月课程 | 化学仿制药药学研究关键技术要求</title><link>https://mp.weixin.qq.com/s/bPRDDHyvhT6BXPn9dVfHdQ</link><description></description><content:encoded><![CDATA[4月课程 | 化学仿制药药学研究关键技术要求]]></content:encoded><pubDate>Fri, 02 Apr 2021 07:37:05 +0800</pubDate></item><item><title>巨星陨落！吉利德传奇CEO John Martin去世</title><link>https://mp.weixin.qq.com/s/5eUsARh3sNIxEELbi6hTRQ</link><description></description><content:encoded><![CDATA[巨星陨落！吉利德传奇CEO John Martin去世]]></content:encoded><pubDate>Thu, 01 Apr 2021 07:03:37 +0800</pubDate></item><item><title>亚盛医药发布2020年全年业绩，核心产品商业化在即</title><link>https://mp.weixin.qq.com/s/X4Qv1pGrRvv-7tCdtjJPeA</link><description></description><content:encoded><![CDATA[亚盛医药发布2020年全年业绩，核心产品商业化在即]]></content:encoded><pubDate>Thu, 01 Apr 2021 07:03:37 +0800</pubDate></item><item><title>绿叶制药发布2020全年业绩：创新研发获突破进展，国际化能力优势显著</title><link>https://mp.weixin.qq.com/s/zagNwjcpQYLaVPTFjkC4xw</link><description></description><content:encoded><![CDATA[绿叶制药发布2020全年业绩：创新研发获突破进展，国际化能力优势显著]]></content:encoded><pubDate>Thu, 01 Apr 2021 07:03:37 +0800</pubDate></item><item><title>心血管领域创新药VASCEPA获得欧盟批准降低发生心血管事件适应症</title><link>https://mp.weixin.qq.com/s/aVyTqF68PFcSIDmG1E35WQ</link><description></description><content:encoded><![CDATA[心血管领域创新药VASCEPA获得欧盟批准降低发生心血管事件适应症]]></content:encoded><pubDate>Thu, 01 Apr 2021 07:03:37 +0800</pubDate></item><item><title>胶质母细胞瘤重大进展！歌礼制药3年深入布局肿瘤脂质代谢，肿瘤管线厚积薄发</title><link>https://mp.weixin.qq.com/s/8kVd6ILrVUdK3p4y1ivLVA</link><description></description><content:encoded><![CDATA[胶质母细胞瘤重大进展！歌礼制药3年深入布局肿瘤脂质代谢，肿瘤管线厚积薄发]]></content:encoded><pubDate>Wed, 31 Mar 2021 07:45:57 +0800</pubDate></item><item><title>维昇药业人生长激素TransCon中国III期临床试验按期完成入组目标</title><link>https://mp.weixin.qq.com/s/o0ZTceYtmR4bpHxCK2UCgw</link><description></description><content:encoded><![CDATA[维昇药业人生长激素TransCon中国III期临床试验按期完成入组目标]]></content:encoded><pubDate>Wed, 31 Mar 2021 07:45:57 +0800</pubDate></item><item><title>嘉和生物STING激动剂GB492临床试验申请获得国家药品监督管理局受理</title><link>https://mp.weixin.qq.com/s/GSPMyva8gpBuWzG8lhbY4w</link><description></description><content:encoded><![CDATA[嘉和生物STING激动剂GB492临床试验申请获得国家药品监督管理局受理]]></content:encoded><pubDate>Wed, 31 Mar 2021 07:45:57 +0800</pubDate></item></channel></rss>